Tumor cells frequently display an abnormal number of chromosomes, a phenomenon known as aneuploidy. Tang et al. (2011) now show that aneuploid cells are particularly sensitive to compounds that induce proteotoxic and energy stress. Could this vulnerability lead to new cancer therapies?
More than a century ago, the German zoologist Theodor Boveri suggested that most chromosome combinations that deviate from the norm (aneuploidy) lead to cell death. But he also predicted that some abnormal chromosome distributions promote unrestrained proliferation and tumor formation (Holland and Cleveland, 2009 ). Although about 90% of all solid human tumors contain numerical chromosome aberrations (Weaver and Cleveland, 2006) , the extent to which aneuploidy contributes to tumor development remains a matter of debate (Schvartzman et al., 2010; Weaver et al., 2007) . This discussion has overshadowed efforts to address a related but no less important question-can aneuploidy be targeted for cancer therapy? In this issue, Tang et al. (2011) provide evidence that specific cellular stress resulting from chromosome imbalances can indeed be utilized for killing cancer cells.
Earlier work in yeast or primary mouse embryonic fibroblasts (MEFs) indicates that just one extra chromosome results in important proliferative defects, as well as metabolic and energetic aberrations (Torres et al., 2007; Williams et al., 2008) . These alterations are thought to result from the additional load of proteins encoded by the extra chromosomes. Based on these findings, it has been proposed that cells respond to the aneuploid state by engaging protein degradation and folding pathways to correct the protein overload caused by the chromosome imbalance. This cellular response is called proteotoxic stress, and it is accompanied by additional energetic requirements. Whether energy and proteotoxic stress can be targeted as druggable, nononcogene addiction pathways represents the starting point of the investigation reported by Tang et al.
By using euploid or aneuploid MEFs carrying Robertsonian fusion chromosomes, the authors investigate whether aneuploid cells are uniquely sensitive to a variety of compounds targeting different pathways. A few compounds are actually poorly tolerated by euploid cells, suggesting that extra copies of genes in aneuploid cells might be protective against a particular drug's toxic effects. Interestingly, the autophagy inhibitor chloroquine, the heat shock protein 90 (Hsp90) inhibitor 17-AAG, and the inducer of the AMP-activated protein kinase (AMPK) AICAR displayed increased selectivity against trisomic MEFs. Two of these molecules, AICAR and 17-AAG, also display some selectivity against chromosomally unstable MEFs with specific alterations in BubR1 or Cdc20, two proteins whose precise regulation controls fidelity during chromosome segregation (Baker et al., 2005) . In addition, AICAR and 17-AAG are more efficient at inhibiting the proliferation of human colorectal cancer cell lines with chromosomal instability when compared to similar tumor cells with microsatellite instability. Comparable results are also found in aneuploid lung tumor cells. Interestingly, all of these aneuploid tumor cells displayed marked sensitivity against the combination of these molecules at low doses (Tang et al., 2011) .
What do these inhibitors have in common, and why do they affect the proliferation of aneuploid cells? The answer is the selective triggering of apoptosis. In primary aneuploid cells, the effect of AICAR is mediated through its target, AMPK. This kinase phosphorylates p53 on serine 15, and the subsequent stabilization of this tumor suppressor results in the induction of proapoptotic Bax. However, p53 is also activated by other compounds that do not show selectivity against aneuploid MEFs. In addition, AICAR and 17-AAG are similarly effective in p53 null human tumor cells. In search of an explanation for these results, Tang et al. analyze several markers of the cellular stress induced by aneuploidy. For instance, aneuploid cells express higher levels of two mediators of autophagy, LC3 and Bnip3, as well as increased levels of Hsp72, a chaperone involved in protein folding. Treatment with AICAR results in a further increase in the level of these markers in aneuploid cells compared to euploid cells. These results suggest that the selectivity of a given drug relies on its capacity to synergize with the basal stress levels existing in aneuploid cells. This suggestion is in agreement with the fact that the effect of AICAR, 17-AAG, or the combination of both directly correlates with the size of the additional chromosome and therefore depends on the protein overload in aneuploid cells.
The results by Tang et al. support the argument that compounds that exacerbate the basal stress state exhibited by aneuploid cells could be effective against aneuploid tumors, irrespective of their origin or their p53 status. Both AICAR and 17-AAG display some toxicity against euploid cells. However, at low concentrations, they can synergize with basal proteotoxic and energy stress present in aneuploid cells, thus opening a window of opportunity for specific treatments against tumor cells (Figure 1) . Given that the basal stress depends on the protein overload, these drugs are likely to be more effective in highly aneuploid cells, a feature of many human cancers (Weaver and Cleveland, 2006 ). Yet, whether energy and proteotoxic stress are a general feature of aneuploid cells needs to be further tested in different human tumors. The recent finding that aneuploid yeast strains proliferate better in some culture conditions (Pavelka et al., 2010) suggests that tumor cells could select aneuploid compositions favorable for their growth in vivo. Thus, the effect of AICAR or 17-AAG, or of other small molecules targeting these pathways, needs to be tested in each specific tumor type. For instance, both AICAR and 17-AAG were effective against aneuploid colorectal tumor cells, whereas only a subset of lung tumor cells were sensitive to AICAR (Tang et al., 2011) , suggesting that not all aneuploidies are equal. A meta-analysis of gene expression profiles in aneuploid versus euploid tumor cells may help to identify markers of the proteotoxic response and perhaps predict the effect of these drugs on different tumor types.
In addition, the correlation between the efficacy of these drugs and protein overload should also be tested in vivo using cancer cells engineered to harbor different chromosome compositions. If these results are confirmed, one could predict that treating cancer cells with drugs that increase aneuploidy by preventing chromosome alignment or by abrogating the mitotic checkpoint could synergize with drugs against the proteotoxic and energy stress induced by aneuploidy (Figure 1 ). The inhibition of chromosome alignment induced by microtubule poisons such as taxol may have such an effect. Also, abrogation of the mitotic checkpoint by using BubR1 or Mps1 kinase inhibitors may represent an alternative mechanism. In fact, taxol and Mps1 downregulation cooperate to elevate the frequency of missegregation of chromosomes in tumor cells (Janssen et al., 2009) . Whether AICAR and 17-AAG might synergize with microtubule poisons or mitotic checkpoint abrogators remains to be tested. It will be crucial in future work to further explore these or other therapeutic opportunities afforded by the energy and proteotoxic stress present in aneuploid cells. The unbalanced protein load in aneuploid cells may result in energy and proteotoxic stress that increase the susceptibility of these cells to apoptotic death. Due to this basal level of stress, these aneuploid cells are more sensitive to specific small molecule compounds that target these pathways, such as the stress-inducing agent AICAR or the protein folding inhibitor 17-AAG. The sensitivity of cells to these drugs is likely to be proportional to the increased protein load in highly aneuploid cells, a condition that is frequently present in human tumors or that may be forced with drugs that prevent fidelity during chromosome segregation. The differential sensitivity of these cells to stressinducing compounds provides a new window of opportunity for specifically targeting cancer cells.
